Marinus Pharmaceuticals (NASDAQ:MRNS) Given “Neutral” Rating at HC Wainwright

Marinus Pharmaceuticals (NASDAQ:MRNS)‘s stock had its “neutral” rating restated by analysts at HC Wainwright in a report issued on Thursday,Benzinga reports. They presently have a $2.00 price objective on the biopharmaceutical company’s stock.

Several other brokerages have also weighed in on MRNS. StockNews.com began coverage on Marinus Pharmaceuticals in a report on Sunday. They issued a “hold” rating for the company. Jefferies Financial Group reissued a “hold” rating and issued a $0.50 price target (down previously from $5.00) on shares of Marinus Pharmaceuticals in a report on Friday, October 25th. JMP Securities restated a “market perform” rating on shares of Marinus Pharmaceuticals in a research note on Thursday, October 24th. EF Hutton Acquisition Co. I upgraded Marinus Pharmaceuticals to a “strong-buy” rating in a research note on Monday, September 30th. Finally, Oppenheimer raised shares of Marinus Pharmaceuticals from a “market perform” rating to an “outperform” rating and set a $6.00 price target for the company in a report on Monday, September 23rd. Nine equities research analysts have rated the stock with a hold rating, two have given a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat, Marinus Pharmaceuticals currently has a consensus rating of “Hold” and a consensus price target of $4.79.

Marinus Pharmaceuticals Trading Down 12.4 %

Marinus Pharmaceuticals stock opened at $0.30 on Thursday. Marinus Pharmaceuticals has a 52 week low of $0.26 and a 52 week high of $11.26. The stock has a market cap of $16.65 million, a P/E ratio of -0.12 and a beta of 1.26. The stock has a 50 day moving average of $1.28 and a 200-day moving average of $1.34.

Marinus Pharmaceuticals (NASDAQ:MRNS) last posted its quarterly earnings results on Tuesday, November 12th. The biopharmaceutical company reported ($0.42) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.44) by $0.02. The firm had revenue of $8.54 million for the quarter, compared to analysts’ expectations of $8.95 million. Marinus Pharmaceuticals had a negative net margin of 446.48% and a negative return on equity of 7,831.35%. As a group, equities analysts predict that Marinus Pharmaceuticals will post -1.92 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

A number of hedge funds have recently made changes to their positions in the stock. Point72 DIFC Ltd acquired a new stake in Marinus Pharmaceuticals in the 2nd quarter valued at about $28,000. SG Americas Securities LLC acquired a new stake in Marinus Pharmaceuticals during the second quarter valued at approximately $34,000. AQR Capital Management LLC lifted its stake in Marinus Pharmaceuticals by 70.3% during the second quarter. AQR Capital Management LLC now owns 31,333 shares of the biopharmaceutical company’s stock valued at $37,000 after purchasing an additional 12,934 shares during the last quarter. Jacobs Levy Equity Management Inc. bought a new stake in Marinus Pharmaceuticals during the first quarter worth approximately $384,000. Finally, Point72 Asia Singapore Pte. Ltd. acquired a new position in Marinus Pharmaceuticals in the second quarter worth approximately $64,000. Institutional investors and hedge funds own 98.80% of the company’s stock.

About Marinus Pharmaceuticals

Marinus Pharmaceuticals, Inc, a pharmaceutical company, focuses on development and commercialization of therapeutic products for patients suffering from rare genetic epilepsies and other seizure disorders. It offers ZTALMY (ganaxolone), an oral suspension for the treatment of seizures associated with cyclin-dependent kinase-like 5 deficiency disorder for adult and pediatric patient populations in acute and chronic care, and in-patient and self-administered settings.